You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 6,194,150

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,194,150

Title:	Nucleic acid based inhibition of CD40
Abstract:	Nucleic acid molecule which blocks synthesis and/or expression of an mRNA encoding B7-1, B7-2, B7-3 and/or CD40.
Inventor(s):	Stinchcomb; Dan T. (Boulder, CO), Jarvis; Thale (Boulder, CO), McSwiggen; James (Boulder, CO)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	09/038,073
Patent Claims:	1. A nucleic acid molecule which specifically blocks expression of a transcript encoding human or mouse CD40, wherein said nucleic acid molecule is selected from the group consisting of an antisense nucleic acid molecule and an enzymatic nucleic acid molecule. 2. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is an enzymatic nucleic acid molecule. 3. The nucleic acid molecule of claim 2, wherein, the binding arms of said enzymatic nucleic acid molecule comprise sequences complementary to any of nucleotide base sequences in Tables X and XII. 4. The nucleic acid molecule of claim 2, wherein said enzymatic nucleic acid molecule is in a hammerhead motif. 5. The nucleic acid molecule of claim 2, wherein said enzymatic nucleic acid molecule is in a hairpin, hepatitis Delta virus, group I intron, VS nucleic acid or RNaseP nucleic acid motif. 6. The nucleic acid molecule of claim 2, wherein said enzymatic nucleic acid molecule comprises between 12 and 100 bases complementary to a portion of RNA encoding said CD40. 7. The nucleic acid molecule of claim 6, wherein said enzymatic nucleic acid molecule comprises between 14 and 24 bases complementary to the RNA. 8. A mammalian cell in vitro including a nucleic acid molecule of claim 1. 9. The mammalian cell of claim 8, wherein said mammalian cell is a human cell. 10. An expression vector comprising a nucleic acid sequence encoding the nucleic acid molecule of claim 1, in a manner which allows expression and/or delivery of said nucleic acid molecule. 11. A mammalian cell in vitro including the expression vector of claim 10. 12. The mammalian cell of claim 11, wherein said mammalian cell is a human cell. 13. The nucleic acid molecule of claim 4, wherein said hammerhead motif comprises any of nucleotide sequence shown in Tables XI and XIII. 14. The nucleic acid molecule of claim 2, wherein, the binding arms of said enzymatic nucleic acid molecule comprise sequences complementary to any of substrate nucleotide base sequences in Tables XVIII and XIX. 15. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is an antisense nucleic acid molecule. 16. The nucleic acid molecule of claim 15, wherein, said antisense nucleic acid molecule is complementary to any of nucleotide sequence in Tables X and XII. 17. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises a chemical modification. 18. The nucleic acid molecule of claim 17, wherein said chemical modification is a sugar modification. 19. The nucleic acid molecule of claim 18, wherein said sugar modification is 2'-O-methyl or 2'H or a combination of 2'-O-methyl and 2'H. 20. The nucleic acid molecule of claim 17, wherein said chemical modification is a nucleotide base modification. 21. The nucleic acid molecule of claim 17, wherein said chemical modification is a phosphodiester backbone modification. 22. The nucleic acid molecule of claim 17, wherein said phosphodiester backbone modification is phosphorothioate. 23. The nucleic acid molecule of claim 2, wherein said enzymatic nucleic acid molecule is able to specifically cleave RNA encoded by said gene. 24. A method of blocking the expression of CD40 gene in vitro, comprising the step of contacting RNA encoded by said CD40 gene with the nucleic acid molecule of claim 1 under conditions suitable for said blocking. 25. The method of claim 23, wherein said nucleic acid molecule is an enzymatic nucleic acid molecule. 26. The method of claim 23, wherein said nucleic acid molecule is an antisense nucleic acid molecule.

Details for Patent 6,194,150

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986	⤷ Try a Trial	2015-07-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132		⤷ Try a Trial	2015-07-07
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132		⤷ Try a Trial	2015-07-07
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.